Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2013-07-18 Board/Management Inform…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
CEO and Director Changes 2 pages 23.0KB
Board/Management Information Classification · 100% confidence The document is a market announcement from the Australian Securities Exchange platform regarding the appointment of a new CEO and other senior management changes at Phylogica Limited. It details the new CEO's background, the retirement and role changes of other executives, and the company's strategic restructuring. There is no financial data, no mention of a report or financial results, and the content focuses solely on management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 4986 characters, which is consistent with a typical management announcement rather than a full report or presentation.
2013-07-18 English
Grant Received for Phylomer Based Biosensor Device 2 pages 24.2KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Ltd regarding a grant received for a biosensor device project. It discusses the collaboration, project goals, and background information about the company and its partners. There is no financial data, no report or filing referenced, no voting results, no management changes, no earnings or interim report, no audit or regulatory filing, and no mention of any corporate governance or capital changes. The content is an announcement of a grant and collaboration, which fits best under a general regulatory announcement category. It is not a report or financial filing but a corporate news release.
2013-07-03 English
Janssen Collaboration Expanded 2 pages 29.2KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Ltd regarding the expansion of a collaboration with Janssen for peptide-drug conjugates. It is a press release-style update about a business development and partnership expansion, with no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4423 characters) and focuses on a corporate collaboration update rather than financial results or governance matters. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The content is best classified as a general regulatory announcement or corporate update that does not fit into more specific categories, making Regulatory Filings (RNS) the most appropriate classification.
2013-06-30 English
New Patent to Discover Sophisticated Cell Penetrating Drugs 2 pages 28.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Ltd dated 27 June 2013, describing a new patented technology enhancement to their peptide drug discovery platform. It discusses the technology, its applications, and upcoming presentations at scientific conferences. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no mention of report attachments or filings. The content is a corporate announcement about technology and patent development, typical of a general regulatory announcement to the market. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. Given the nature and length of the document, and that it is a public announcement of company developments, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2013-06-26 English
Change of Director's Interest Notice 2 pages 27.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, nature of the interest, and transaction details such as on-market purchase. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not an annual report, earnings release, or any other financial report but specifically a director's dealing notice. The document length is under 5,000 characters and contains detailed transaction data, confirming it is a Director's Dealing report.
2013-05-05 English
European Patent Granted 2 pages 106.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Ltd regarding the granting of a European patent related to their Phylomer peptides for ischemia. It is a brief announcement about intellectual property and does not contain financial data, management changes, voting results, or detailed financial reports. It is not a report publication announcement since it does not mention any report being attached or published. The content is a regulatory announcement about a patent grant, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2013-04-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.